Special Issue

Personalized Medicine in Post-COVID-19 Era

Message from the Guest Editors

Concerning the post-COVID patients, personalized medicine is of significant medical interest. The identification of biomarkers that could guide the personalized approach of these patients could allow for the identification of the most effective diagnosis and treatment methods. The Special Issue will highlight the importance of understanding the main factors that influence individual responses to the virus and lead to more targeted and effective treatment strategies. In addition, it will focus on why certain individuals are more prone to long COVID and how to manage their symptoms more effectively. We hope that research tools such as proteomics, genomics, metabolomics and epigenomics will allow for the identification of guidelines for a personalized approach, and could help identify the patients who may need alternative vaccination strategies. Personalized medicine can help in identifying existing drugs that may be more effective for certain subgroups of COVID-19 patients, leading to potential drug repurposing for better outcomes.

Guest Editors

Prof. Dr. Cristian Oancea

Pulmonology Department, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania

Dr. Elena Cojocaru

Morpho⊠Functional Sciences II Department, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, Iaşi, Romania

Deadline for manuscript submissions

closed (20 June 2025)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/178268

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

